A model for building a national, patient-driven database to track contraceptive use in women with rare diseases.
J Am Med Inform Assoc
; 29(2): 348-353, 2022 01 12.
Article
in En
| MEDLINE
| ID: mdl-34679174
Data on the safety and effectiveness of contraception among women with rare diseases are critical and sorely lacking. To fill this gap, we propose a national, patient-driven database that tracks contraceptive safety and effectiveness among women with rare diseases. We built a pilot database focusing on women with cystic fibrosis in 3 phases: (1) database design input from patients and experts, (2) merging of contraceptive survey data with relevant clinical outcomes from the Cystic Fibrosis Foundation Patient Registry (CFFPR), and (3) forming a data guide to facilitate accessible output data. We successfully linked 62 contraceptive survey variables with 362 relevant clinical outcome variables for 150 patients. This pilot represents a breakthrough in linking contraceptive data to disease-specific outcomes and informs how to build a national, patient-driven contraceptive database for women with rare diseases.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Contraceptive Agents
/
Cystic Fibrosis
Type of study:
Prognostic_studies
/
Qualitative_research
Limits:
Female
/
Humans
Language:
En
Journal:
J Am Med Inform Assoc
Journal subject:
INFORMATICA MEDICA
Year:
2022
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom